The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy

Figures & data

Table 1. Group information of each immunization program

sIPV/OPV sequential immunization programs	No. of enrolled subject	No. Of analyzed subject	cIPV/OPV sequential immunization programs	No. of enrolled subject	No. Of analyzed subject
1sIPV+2bOPV	200	167	1cIPV+2bOPV	200	164
2sIPV+1bOPV	200	162	2cIPV+1bOPV	200	154
2sIPV+1tOPV	200	159	2cIPV+1tOPV	200	162

sIPV: Sabin inactivated poliovirus vaccine; cIPV: Salk inactivated poliovirus vaccine; bOPV: bivalent type 1 + 2 oral poliovirus vaccine; tOPV: trivalent oral poliovirus vaccine.

Figure 1. Vaccination procedures used in this study.

PV: polio vaccine; HepB: hepatitis B vaccine; HepA-L: live attenuated hepatitis A vaccine.

Table 2. Demographic characteristics of participants

		1sIPV+2bOPV (n = 167)	2sIPV+1bOPV (n = 162)	2sIPV+1tOPV (n = 159)	1cIPV+2bOPV (n = 164)	2cIPV+1bOPV (n = 154)	2cIPV+1tOPV (n = 162)	P value
Sex, n (%)	Male	94(56.29%)	88(54.32%)	81(50.94%)	80(48.78%)	89(57.79%)	83(51.23%)	0.567^a
	Female	73(43.71%)	74(45.68%)	78(49.06%)	84(51.22%)	65(42.21%)	79(48.77%)
Race, n (%)	Han	58(34.73%)	40(24.69%)	45 (28.30%)	51(31.10%)	53(34.42%)	55(33.95%)	0.297^a
	Minorities	109(65.27%)	122(75.31%)	114(71.70%)	113(68.90%)	101(65.58%)	107(66.05%)
Height, cm	Average(95%CI)	59.66(59.32–60.01)	59.59(59.27–59.92)	59.79(59.46–60.11)	59.43(59.12–59.75)	59.60(59.26–59.94)	59.47(59.12–59.82)	0.583^b
Weight, kg	Average(95%CI)	5.81(5.70–5.93)	5.73(5.63–5.82)	5.76(5.64–5.89)	5.68(5.59–5.79)	5.72(5.62–5.83)	5.65(5.55–5.76)	0.483^b

a. Statistics using Pearson’s chi-square test.

b. Statistics using Kruskal-Wallis H test.

Table 3. Immunization effect of hepatitis A vaccine

	1sIPV+2bOPV (n = 167)	2sIPV+1bOPV (n = 162)	2sIPV+1tOPV (n = 159)	1cIPV+2bOPV (n = 164)	2cIPV+1bOPV (n = 154)	2cIPV+1tOPV (n = 162)	P value
Before polio vaccination (2 months of age)
Positive rate (%)	76.65%	74.69%	75.47%	78.05%	79.87%	74.07%	0.834^a
Mean value (IU/L)	1971.72	1944.02	1517.44	1910.46	1941.59	1886.39	0.412^b
28 days after primary polio vaccination (5 months of age)
Positive rate (%)	73.65%	75.93%	76.73%	71.34%	78.57%	71.60%	0.612^a
Mean value (IU/L)	506.90	471.14	402.11	432.37	468.34	423.39	0.676^b
24 months of age
Positive rate (%)	100%	100%	99.37%	98.78%	98.05%	100%	0.134^a
Mean value (IU/L)	577.75	565.86	608.75	666.94	564.45	564.61	0.556^b

a. Antibody positive rate using Pearson’s chi-square test.

b. Antibody concentration using Kruskal-Wallis H test.

Table 4. Immunization effect of hepatitis B vaccine

	1sIPV+2bOPV (n = 167)	2sIPV+1bOPV (n = 162)	2sIPV+1tOPV (n = 159)	1cIPV+2bOPV (n = 164)	2cIPV+1bOPV (n = 154)	2cIPV+1tOPV (n = 162)	P value
Before polio vaccination (2 months of age)
Positive rate (%)	97.01%	97.53%	96.23%	93.90%	96.75%	97.53%	0.484^a
Mean value (IU/L)	822.88	1072.51	949.53	1016.19	807.91	754.46	0.178^b
28 days after primary polio vaccination (5 months of age)
Positive rate (%)	100%	99.38%	99.37%	100%	98.70%	100%	0.378^a
Mean value (IU/L)	1255.78	1684.97	1510.83	1574.95	1160.94	1405.83	0.048^b
24 months of age
Positive rate (%)	87.43%	86.42%	84.28%	85.98%	88.31%	86.42%	0.938^a
Mean value (IU/L)	642.95	618.34	613.05	771.81	990.13	624.18	0.987^b

a. Antibody positive rate using Pearson’s chi-square test.

b. Antibody concentration using Kruskal-Wallis H test.